Order Article Reprints

Polerà N, Mancuso A, Riillo C, Caracciolo D, Signorelli S, Grillone K, Ascrizzi S, Hokanson CA, Conforti F, Staropoli N, et al. The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas. Cancers. 2023; 15(6):1647. https://doi.org/10.3390/cancers15061647

Polerà, Nicoletta, Antonia Mancuso, Caterina Riillo, Daniele Caracciolo, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Craig A. Hokanson, Francesco Conforti, Nicoletta Staropoli, and et al. 2023. "The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas" Cancers 15, no. 6: 1647. https://doi.org/10.3390/cancers15061647

Polerà, N., Mancuso, A., Riillo, C., Caracciolo, D., Signorelli, S., Grillone, K., Ascrizzi, S., Hokanson, C. A., Conforti, F., Staropoli, N., Gervasi, L., Di Martino, M. T., Arbitrio, M., Nisticò, G., Crea, R., Tagliaferri, P., Juli, G., & Tassone, P. (2023). The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas. Cancers, 15(6), 1647. https://doi.org/10.3390/cancers15061647